Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kun Yi Ning granules is a traditional Chinese medicine (TCM) formulation developed by the Zhejiang Institute of Traditional Chinese Medicine for the treatment of perimenopausal syndrome. It is specifically indicated for patients presenting with the traditional Chinese medicine pattern of "kidney yin and yang deficiency." The drug is designed to alleviate perimenopausal symptoms such as hot flashes, sweating, insomnia, and irritability by regulating the hypothalamic-pituitary-ovarian axis and balancing sex hormone levels, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2). It has been evaluated in a randomized, double-blind, placebo-controlled Phase II clinical trial in China, where it demonstrated efficacy in improving Kupperman scores and TCM symptom scales over an 8-week treatment period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kun yi ning granules.